More on IRD
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $4.60 |
|
|||
| Open | $4.53 | ||||
| 52 Wk High | $0.02 | ||||
| 52 Wk Low | $0.02 | ||||
| Day High | $4.80 | ||||
| Day Low | $4.40 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 2,239,734 | ||||
- Opus Genetics (IRD) Reiterated at Market Outperform by Citizens: Focus on Viatris
- Longeveron names Nirav Jhaveri as CFO
- Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
- Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- TD Cowen on Opus Genetics (IRD): 'High Conviction For Meaningful Efficacy'
- Opus Genetics (IRD) Reiterated at Market Outperform by Citizens Ahead of Phase 1/2 BIRD-1 Trial
- Form EFFECT Opus Genetics, Inc.
- Form SCHEDULE 13G/A Opus Genetics, Inc. Filed by: PERCEPTIVE ADVISORS LLC
- Form SCHEDULE 13G/A Opus Genetics, Inc. Filed by: Caligan Partners LP
- Form SCHEDULE 13G/A Opus Genetics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
Entities mentioned with IRD
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- S3 | View Related Stories »
- Show More...
